Ethos Technologies Inc (LIFE) Stock Price, Quote & News

ParagonStar1 Feb. 3 at 12:09 PM

0 · Reply

seekingyield1 Feb. 2 at 8:57 PM

$LIFE shattered IPO trading at ~8x EBITDA and ~12-13x Q4's annualized EPS (similar to 9mo annualized). Think it has been caught up as a software company or something, but it is more of a GSHD like insurance originator earning commission revenue. The value is in the network effects of agents using their platform and insurance companies paying for their origination leads. Cash flow positive, Q4 growth is over 60% and EPS probably doubles When they officially report Q4 we may see a nice 2026 guide - it is certainly not priced for one, particularly given the incentives a recent IPO has to go public when the business has momentum

0 · Reply

no_cry Feb. 2 at 7:11 PM

$LIFE $19 IPO. Got saved

0 · Reply

Forex_Crypto Feb. 2 at 4:29 PM

$LIFE Great company. Question is... what is this stock worth? $13, $14, $15, or $16

1 · Reply

underdemeciated Feb. 2 at 3:59 PM

$LIFE "very limited shares available at IPO" Proceeds to IPO and tank. What a scam. Glad I only grabbed one at 17. Didn't think it would be a slaughter. Oh well. Typical atp. 19$ IPO price.

0 · Reply

Gareltofrivia Feb. 2 at 3:47 PM

$LIFE wow, this was a huge turd

0 · Reply

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

May 14, 2024, 8:00 AM EDT - 1 year ago

aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

aTyr Pharma to Present at November Investor Conferences

Sep 11, 2023, 8:00 AM EDT - 2 years ago

aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

Aug 24, 2023, 8:00 AM EDT - 2 years ago

aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 9, 2023, 4:00 PM EDT - 2 years ago

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

Jun 20, 2023, 8:00 AM EDT - 2 years ago

aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

May 25, 2023, 8:00 AM EDT - 2 years ago

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies

aTyr Pharma, Inc. (LIFE) Q4 2022 Earnings Call Transcript

Mar 10, 2023, 5:12 PM EST - 3 years ago

0 · Reply

seekingyield1 Feb. 2 at 8:57 PM

0 · Reply

no_cry Feb. 2 at 7:11 PM

$LIFE $19 IPO. Got saved

0 · Reply

Forex_Crypto Feb. 2 at 4:29 PM

$LIFE Great company. Question is... what is this stock worth? $13, $14, $15, or $16

1 · Reply

underdemeciated Feb. 2 at 3:59 PM

$LIFE "very limited shares available at IPO" Proceeds to IPO and tank. What a scam. Glad I only grabbed one at 17. Didn't think it would be a slaughter. Oh well. Typical atp. 19$ IPO price.

0 · Reply

Gareltofrivia Feb. 2 at 3:47 PM

$LIFE wow, this was a huge turd

0 · Reply

Market Cap	131.12M
Revenue (ttm)	350,000.00
Net Income (ttm)	-50.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-14,397.14%
Debt to Equity Ratio	0.00

Volume	963,100
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	69.01M
Stochastic %K	N/A
Beta	1.19
Analysts	Strong Sell
Price Target	$23.67